Clinical application of personalized ddPCR assays in liquid profiling of blood and saliva allows early recurrence detection of head and neck tumors

Early relapse detection by monitoring of circulating cell-free DNA in patients with localized head and neck squamous cell carcinoma: A subgroup analysis of the multicenter randomized clinical trial IMSTAR-HN

“…It suggests that persistent or newly emerging ctDNA has the potential to identify patients at risk for disease recurrence after treatment with curative intent. Thereby, it adds to a still rather small body of evidence on ddPCR-based liquid biopsies in HNSCC as personalized tool for sensitive disease monitoring [19][20][21][22].…”